Vyriad
Dr. Bexon brings to Vyriad more than 20 years of management experience in clinical development of biopharmaceuticals, including management of multi-site clinical trials and FDA approval of lead assets. Prior to joining Vyriad, Dr. Bexon founded Bexon Clinical Consulting, which provides clinical development support to the pharma and biotech industries. Previously, Dr. Bexon was Vice President of Clinical Development of Idera Pharmaceuticals, from 2007-2009. From 2001-2006, she held a number of positions of increasing responsibility at Roche Oncology, including serving as a key member of the clinical development and life cycle team responsible for Xeloda®. Dr. Bexon earned her medical degree from Bristol University Medical School in the United Kingdom and her oncology diploma at the Institut Gustave Roussy in France.
This person is not in any offices
Vyriad
Vyriad is developing the next generation of targeted cancer therapies using engineered viruses that selectively attack cancer cells and ignite robust immune responses to prevent cancer recurrence.